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BACKGROUND: Temsirolimus was approved in Europe as first-line treatment of poor-prognosis advanced renal cell carcinoma
(advRCC) based on significant clinical benefits.
METHODS: Patients with advRCC and multiple poor-prognostic factors were randomly assigned to receive 25mg intravenous
temsirolimus weekly, interferon-a (titrated to 18mU) three times weekly, or 15mg intravenous temsirolimus weekly plus 6mU of
interferon-a three times weekly. EuroQol-5D utility score (EQ-5D index) and the EQ-5D visual analogue scale (EQ-VAS) responses
were recorded. For analysis, patients were required to have their EQ-5D data recorded at baseline, week 12, and last visit after week
12. The analysis was conducted using last-visit data and a repeated-measures mixed-effect (RMME) model to evaluate quality-of-life
differences between temsirolimus and interferon-a, controlling for baseline covariates.
RESULTS: Average EQ-5D score at the last measure was significantly higher in patients receiving temsirolimus compared with
interferon-a: by 0.10 on EQ-5D index (P¼0.0279) and by 6.61 on EQ-VAS (P¼0.0095). In the RMME model, the least-square
mean for on-treatment EQ-5D index score was 0.590 with temsirolimus and 0.492 with interferon-a (P¼0.0022).
CONCLUSION: Temsirolimus is associated with significantly higher EQ-5D scores compared with interferon-a in patients with previously
untreated poor-prognosis advRCC.
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Renal cell carcinoma (RCC) is the most common and lethal form of
kidney cancer, accounting for 80–90% of renal cancers and 2.6%
of adult cancers (Mathew et al, 2002; Hudes et al, 2007; Wein et al,
2007; Cella et al, 2008; Jemal et al, 2008). Renal cell carcinoma is
twice as frequent in men as in women, and most commonly affects
patients aged 50–80 years. More than 40% of patients with RCC
die of the cancer, compared with 20% of patients with prostate or
bladder cancer (Wein et al, 2007). Only 20% of patients with
advanced RCC (advRCC) survive for 5 years (Cella et al, 2008).
Advanced RCC is refractory to conventional chemotherapy
(Brugarolas, 2007; Motzer et al, 2007) and has long been managed
with cytokine-based therapies (van Spronsen et al, 2005). Interferon-a
(IFN-a) prolongs overall survival in some patients (van Spronsen et al,
2005). Adverse events with IFN-a can impact quality of life (QOL).
The advent of targeted therapies has contributed to a paradigm
shift in metastatic RCC management (Coppin et al, 2008).
Temsirolimus (CCI-779 or Torisel, Pfizer, New York, NY, USA)
is a specific inhibitor of the mammalian target of rapamycin kinase
that provides survival benefits as first-line therapy in patients with
advRCC and a poor prognosis (Brugarolas, 2007; Hudes et al, 2007;
Coppin et al, 2008; Motzer et al, 2008). By inhibiting mammalian
target of rapamycin kinase, temsirolimus reduces translation of a
variety of messenger RNA, including those for key transcription
factors, which is a step in the signalling cascade for angiogenesis
and has been implicated in the development of clear-cell renal tumours.
In the international, randomised, phase III study (Global
Advanced Renal Cell Carcinoma (ARCC) trial; ClinicalTrials.gov
study no. NCT00065468; Hudes et al, 2007), temsirolimus was
associated with a significant overall survival benefit compared with
IFN-a (median overall survival¼10.9 vs 7.3 months; hazard ratio
for death¼0.73 (95% confidence interval (CI)¼0.58, 0.92);
P¼0.008) and progression-free survival benefit as first-line
treatment for poor-prognosis advRCC. Quality-adjusted survival
data, assessed by quality-adjusted time without symptoms of
progression or toxicity (Q-TWiST), have been reported previously
(Zbrozek et al, 2010). The objective of this study was to evaluate,
among patients in the Global ARCC trial, QOL as assessed by the
EuroQol-5D utility score (EQ-5D index) and the EQ-5D visual
analogue scale (EQ-VAS), which were two protocol-specified
questionnaires administered during the trial.
PATIENTS AND METHODS
Treatments
This study is an analysis reporting QOL data among a subgroup of
626 patients with previously untreated, poor-prognosis advRCC
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sfrom Global ARCC (Hudes et al, 2007; National Institutes of
Health, 2007). Eligible patients were enroled between July, 2003
and April, 2005, and randomly assigned to 25mg of intravenous
(i.v.) temsirolimus weekly or 3–18mU of subcutaneous IFN-a
(IFN-a2a; Roferon-A, Roche Pharmaceuticals, Nutley, NJ, USA)
three times weekly (Roferon-A, 2008 (US full prescribing informa-
tion)). A third group was randomised to combination therapy, but was
not included in this analysis because there was no survival advantage.
Patients
Eligible patients had histologically confirmed advRCC (stage IV or
recurrent disease); a Karnofsky performance score of X60; no
previous systemic treatment; a measurable tumour according to
response evaluation criteria in solid tumours (RECIST; Therasse
et al, 2000); adequate bone marrow, kidney, and liver functions;
and fasting levels of total cholesterol and triglyceride below
specified levels (Hudes et al, 2007). Patients were required to have
at least three of six predictors of short survival to qualify as having
poor prognosis. The six predictors included the five Memorial
Sloan-Kettering Cancer Center (MSKCC) prognostic factors: o1
year from time of initial RCC diagnosis to randomisation; a
Karnofsky performance status of 60 or 70; haemoglobin level less
than the lower limit of normal; corrected calcium 42.5mmoll
 1;
and serum lactate dehydrogenase 41.5 times the upper limit of
normal (Motzer et al, 1999, 2002; Mekhail et al, 2005). The
remaining predictor was more than one metastatic organ site of
disease (Mekhail et al, 2005).
QOL assessments
Self-reported QOL was evaluated using the EQ-5D questionnaire
(The EuroQol Group, 1990; Oppe et al, 2008). It is designed to
cover common areas of health QOL (Brooks, 1996). The EQ-5D
was found to have responsiveness comparable to that of the
European Organisation for Research and Treatment of Cancer
Quality of Life Questionnaire C-30 (Krabbe et al, 2004). The EQ-5D
is particularly well suited for international trials because it has
been validated and translated into more than 100 languages (Oppe
et al, 2008). It consists of two pages: the first with descriptive
questions that generate the EQ-5D index score (the utility score)
and the second with the EQ-VAS (Oppe et al, 2008).
The EQ-5D descriptive system has five dimensions: mobility,
self-care, usual activities, pain/discomfort, and anxiety/depression
(Oppe et al, 2008). Patients can respond to a question on each
dimension by marking a box corresponding to ‘no problems,’
‘some problems,’ or ‘severe problems’ (scored as 1, 2, and 3,
respectively). These numerals do not have arithmetic properties
and cannot be used as a cardinal scale. A five-digit number can be
created by combining the answers to the five dimensions, and thus
243 health states can be described using this system (Oppe et al,
2008). The EQ-VAS allows patients to rate their health by drawing
a line on a thermometer-like scale from 0–100, in which 0 is the
worst possible health status and 100 the best health condition
(Greiner et al, 2003; Oppe et al, 2008). It has acceptable validity
and excellent reliability as a global QOL measure for clinical trials
(de Boer et al, 2004). The EQ-5D was scored using the index-based
algorithm as described by Dolan (1997).
In this study, patient QOL was measured using the EQ-5D index
and EQ-VAS at screening, week 12, week 32, any visit at which the
patient reported a symptomatic National Cancer Institute Com-
mon Terminology Criteria, version 3.0 grade 3 (severe) or 4 (life-
threatening or disabling) adverse event (unless the medical
condition prohibited using the EQ-5D; National Cancer Institute,
2006), and the withdrawal visit. In this analysis, EQ-5D measures
at week 12 and the last measure were used wherever possible. For
patients with a withdrawal visit recorded, the last measure was defined
as the EQ-5D at the withdrawal visit. For those without a withdrawal
visit recorded, the visit at which the last EQ-5D was recorded was the
last measure. Patients with EQ-5D at screening only or with EQ-5D
data up to week 12 only were excluded from the analyses.
Statistical analysis
Two types of statistical analyses were performed. An analysis of
outcomes between the two treatments at last study visit was
conducted, analysing the overall population and subgroups on the
basis of prior nephrectomy status, primary cell type, and a number
of poor-prognosis factors at baseline. For each subgroup, mean EQ-
5D index score and mean EQ-VAS score at last visit by treatment
were computed, as were their differences along with the 95% CIs of
the differences. Two-tailed t-tests at a¼0.05 were conducted for
independent samples to compare outcomes. The null hypothesis was
that there were no differences between the two treatment groups.
The second analysis evaluated mean EQ-5D VAS and index
measures between two treatments using a model controlling for
age, gender, baseline QOL, tumour histology type, MSKCC
prognostic factor status, prior nephrectomy history, and time
since randomisation. Repeated measures indicate multiple
responses taken at different times from the same patients (Littell
et al, 1998). Data analysis of repeated measures permits a
comparison of response trends over time by treatment. The
mixed-model methodology is particularly appropriate because it
accounts for covariance issues in multiple measures of patients’
responses over time. Other advantages of repeated-measures
mixed-effect (RMME) models include their superior flexibility in
modelling time effects, ability to account for correlations among
repeated assessments of the same person, and capacity to account
for missing data (Gueorguieva and Krystal, 2004).
RESULTS
Baseline characteristics
Patients were randomly assigned to temsirolimus (n¼209) or
IFN-a (n¼207) groups. Of these 416 patients, 270 (65%) were
evaluable for QOL analysis: 155 for temsirolimus and 115 for
IFN-a. The two treatment groups were well balanced on the basis
of age, sex, and other characteristics at baseline (Supplementary
Online Table 1), and no baseline characteristic was significantly
different between the two groups (Hudes et al, 2007). The average
patient age was 59 years (s.d.¼10). Approximately 32% of the
patients were females, 85% had clear-cell carcinoma, and 95% had
at least three poor-prognostic factors. The mean EQ-5D utility
score (s.d.) was 0.62 (0.24), and the mean EQ-5D VAS score (s.d.)
was 64.03 (17.17). Approximately 80% of patients in each group
had a Karnofsky performance score of 60 or 70; received a
diagnosis of metastatic RCC within 12 months of enrollment;
haemoglobin below lower limit of normal; and two or more sites of
organ metastases. Approximately two-thirds of the patients in each
treatment group had undergone nephrectomy.
Last-visit analysis
In the last-visit analysis of EQ-5D index scores, temsirolimus was
associated with superior EQ-5D index scores compared with IFN-a
(Figure 1A). The mean EQ-5D index score at last measure was
higher in the temsirolimus arm than in the IFN-a arm by 0.10
(P¼0.0279). Similarly, patients with clear-cell tumour histology
treated with temsirolimus had mean index scores significantly
higher than those treated with IFN-a (P¼0.0395). Patients with at
least three poor-prognostic factors treated with temsirolimus also
had mean index scores significantly higher than those treated with
IFN-a (P¼0.0308).
In a corresponding (last-visit) analysis of EQ-VAS scores,
temsirolimus was associated with superior EQ-VAS scores
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scompared with IFN-a (Figure 1B). The mean EQ-VAS score at last
measure was higher in the temsirolimus arm than the IFN-a arm
by 6.61 (P¼0.0095). In the last-visit analysis of mean EQ-VAS
scores, scores were significantly higher in the temsirolimus arm
compared with the IFN-a arm among patients with no prior
nephrectomy (P¼0.0056) or with clear-cell histology (P¼0.0061),
and/or at least three poor-prognostic factors (P¼0.0056).
RMME analysis
In the RMME model, temsirolimus was also associated with
superior EQ-5D index scores compared with IFN-a. The least-
square mean for on-treatment EQ-5D index scores in the IFN-a
arm was 0.492 (s.e.¼0.031) and in the temsirolimus arm was 0.590
(s.e.¼0.026; P value for difference¼0.0022 (95% CI¼ –0.162,
–0.036)). The other significant covariates (Table 1) were as follows:
patients in the MSKCC intermediate-risk group had on-treatment
EQ-5D index scores higher than those in the poor-risk group
(Po0.0001 (0.080, 0.214)); patients assessed at week 12 had higher
on-treatment EQ-5D index scores compared with patients at the
withdrawal visit (Po0.0001 (0.055, 0.148)); and patients having
higher baseline EQ-5D index scores also had higher on-treatment
EQ-5D scores (Po0.0001 (0.470, 0.733)).
Temsirolimus was associated with significantly greater EQ-5D
VAS scores compared with IFN-a: the least-square mean for the
on-treatment EQ-5D VAS score in the IFN-a arm was 58.83
(s.e.¼1.83) and in the temsirolimus arm was 63.33 (s.e. ¼1.56;
P¼0.0168; 95% CI¼ 8.184,  0.819). As summarised in Table 1,
other significant covariates predicting higher on-treatment EQ-5D
VAS scores included high EQ-5D VAS at baseline, patient
placement in the MSKCC intermediate-risk group, with no prior
nephrectomy, and patient assessment at week 12 compared with
those assessed at their withdrawal visit.
DISCUSSION
This study, to the best of our knowledge, is the first to compare
EQ-5D scores for temsirolimus and IFN-a in previously untreated
patients with advRCC and multiple poor-prognostic factors.
Temsirolimus was associated with significantly higher (improved)
patient-reported EQ-5D compared with IFN-a. At the last study
visit, patients treated with temsirolimus had higher mean EQ-5D
index and EQ-VAS scores compared with those treated with IFN-a.
Consistent with these results, patients treated with temsirolimus
(vs IFN-a) also had higher mean EQ-5D index and EQ-VAS scores
in an RMME analysis. The difference in EQ-5D index scores between
temsirolimus and IFN-a was 0.099. This was greater than the minimally
important difference. The minimally important difference was first
established at 0.05 as a general rule, based on 5% of the instrument’s
maximal score, or as 0.06–0.08 depending on the country (Pickard
et al, 2007; Ringash et al, 2007). Thus, these results for temsirolimus
should be considered clinically and statistically significant.
These findings complement data from the parent Global ARCC
study that found a significant prolongation of overall survival
with temsirolimus compared with IFN-a (Hudes et al, 2007). Our
analysis also extends to findings from the Q-TWiST analysis
(Zbrozek et al, 2010), which demonstrated that patients with
advanced, metastatic RCC receiving temsirolimus have signifi-
cantly longer quality-adjusted survival (by 1.4 months; B25%
increase in Q-TWiST) compared with patients treated with IFN-a.
As Q-TWiST is an index of time spent in different health states and
is not treatment specific, Q-TWiST analyses can result in the same
or a very similar score for a patient with a grade 3 or 4 adverse
event irrespective of whether the event occurred during temsiro-
limus or IFN-a therapy. As the present analysis is treatment
specific, it can serve as a foundation for establishing treatment-
specific utilities for cost-effectiveness analyses. Our examination of
the differences in EQ-5D scores in the two treatment arms suggests
that the increase in quality-adjusted survival associated with
temsirolimus was not a mere artefact of an increased survival time
but was instead a function of the therapy itself.
The RMME models controlling for covariates determined that
the only factors associated with higher on-treatment EQ-5D index
scores were temsirolimus, baseline EQ-5D index scores, MSKCC
intermediate-risk status, and assessment at treatment week 12.
(Besides the above factors, patients with no prior nephrectomy
also had higher EQ-5D VAS scores.) To the best of our knowledge,
this study is the first to report that MSKCC intermediate-risk
status (presence of one or two of the five MSKCC risk factors) was
associated with significantly higher EQ-5D scores than poor-risk
status (presence of at least three MSKCC risk factors; Motzer et al,
1999). This finding strengthens the rationale for using the MSKCC
risk category as a stratification variable or a covariate in clinical
trial designs. Memorial Sloan-Kettering Cancer Center risk factors
are used to stratify patients into three different groups: favourable
risk, intermediate risk, and poor risk (Motzer et al, 1999). The
3-year survival rates for these groups in the MSKCC study were
31%, 7%, and 0%, respectively (Motzer et al, 1999). However,
because this study had only 14 patients (five in the IFN-a arm and
nine in the temsirolimus arm) with less than three risk factors, this
finding may not be generalisable to a larger population that
includes patients with one or two risk factors.
The instruments chosen to document QOL are not cancer
specific because the study was designed to provide data for
Less than 3 poor prognostic factors
3+ poor prognostic factors
Tumor histology – non clear cell
Tumor histology – clear cell
No prior nephrectomy
Prior nephrectomy
All patients
                                             0.4 0.3 0.2 0.1 0 –0.1 –0.2 –0.3
Temsirolimus worse Temsirolimus better
Less than 3 poor prognostic factors
3+ poor prognostic factors
Tumor histology – non clear cell
Tumor histology – clear cell
No prior nephrectomy
Prior nephrectomy
All patients
30 20 10 0 –10 –20 –30 –40 –50
Temsirolimus worse Temsirolimus better
Figure 1 (A) Temsirolimus vs IFN-a mean (95% CI) differences in
EQ-5D index scores at the last study visit. (B) Temsirolimus vs IFN-a mean
(95% CI) differences in EQ-VAS scores at the last study visit. For tumour
histology, the ‘non clear cell’ category includes some patients with indeterminate
histology. Solid horizontal lines, 95% CIs; solid vertical lines, no difference.
CI¼confidence interval, EQ-5D¼EuroQol Group’s 5-dimension questionnaire;
EQ-VAS¼EQ-5D visual analogue scale; IFN¼interferon.
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scross-disease economic analyses. The EQ-5D allows the patient to
rate 243 different health states on a scale from 1 (no health
problems) to 3 (extreme health problems), and the scores can be
used to determine ‘time trade-offs’ between disease states that
facilitate cost-effectiveness and cost-utility analyses. To our
knowledge, the only head-to-head comparison of treatment for
metastatic RCC with a targeted therapy (sunitinib) compared with
IFN-a used the EQ-5D index and EQ-VAS scores, and the data were
consistent with other findings using disease-specific instruments,
including the Functional Assessment of Cancer Therapy-General,
and the Functional Assessment of Cancer Therapy-Kidney
Symptom Index-15 item (Cella et al, 2008).
There was an imbalance in the number (percent) of patients in
the Global ARCC trial who survived, had evaluable EQ-5D data,
and qualified for study enrollment: 155 (74.2%) of 209 original
patients in the temsirolimus arm compared with 115 (55.6%) of
207 in the IFN-a arm. However, the RMME model was designed, in
part, to limit the bias associated with uneven patient attrition in
the two groups; hence, it is reassuring that findings from both
analyses were consistent. Furthermore, an analysis of the causes of
treatment withdrawals (data not shown) found that most (B85%)
of the last visits were occasioned by disease progression and/or
symptomatic deterioration rather than adverse events (B10%).
Even if all 10% of the adverse event-related treatment withdrawals
had been observed in the IFN-a arm, thereby reducing the QOL
associated with this treatment, it is unlikely that this small
proportion would affect the overall conclusions. It is also unlikely,
therefore, that this factor in particular, or selective attrition in
general, would be a substantial source of bias.
Our study evaluated patients at the latest possible point (last
visit) rather than at a fixed time from inception of treatment. Thus,
it is possible that patient-reported QOL is lower in this study
than in studies that used a fixed time for evaluation, rendering
cross-study comparisons more hazardous than usual. Finally,
temsirolimus has not been compared head-to-head with other
targeted treatments in active-comparator trials.
CONCLUSION
Temsirolimus was associated with significantly higher (superior)
EQ-5D scores compared with IFN-a in previously untreated patients
with poor-prognosis advRCC. The improvement in QOL compared
with IFN-a, along with the previously established overall survival
and progression-free survival benefits of temsirolimus (vs IFN-a),
suggests that the inhibitor of mammalian target of rapamycin kinase
could be used as first-line therapy in such patients.
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Table 1 RMME of factors affecting quality of life
RMME results for EQ-5D index scores
Factors Coefficient
a P value 95% CI
Significant impact*
Baseline EQ-5D index score 0.601 o0.0001 (0.470, 0.733)
Treatment, IFN-a (vs temsirolimus)  0.099 0.0022 ( 0.162,  0.036)
Intermediate (vs poor) MSKCC risk 0.147 o0.0001 (0.080, 0.214)
Time of assessment, week 12 (vs withdrawal) visit 0.102 o0.0001 (0.055, 0.148)
No significant impact
Age –0.002 0.1495 ( 0.005, 0.0008)
Female (vs male) gender –0.046 0.1731 ( 0.111, 0.020)
No prior (vs prior) nephrectomy 0.050 0.1383 ( 0.016, 0.116)
Clear-cell (vs non-clear-cell) tumour histology type 0.011 0.7940 ( 0.074, 0.097)
RMME results for EQ-5D VAS scores
Factors Coefficient
a 95% CI
Significant impact*
Baseline EQ-5D VAS score 0.546 (0.439, 0.653)
Intermediate (vs poor) MSKCC risk 6.365 (2.381, 10.349)
No prior (vs prior) nephrectomy 7.220 (3.349, 11.090)
Treatment, IFN-a (vs temsirolimus)  4.501 ( 8.184,  0.819)
Time of assessment, week 12 (vs withdrawal) visit 6.080 (3.372, 8.787)
No significant impact
Age  0.126 ( 0.307, 0.054)
Female (vs male) gender 0.150 ( 3.700, 4.000)
Clear-cell (vs non-clear-cell) tumour histology type 0.968 ( 4.113, 6.049)
Abbreviations: CI¼confidence interval; EQ-5D¼EuroQol Group’s 5-dimension questionnaire; IFN¼interferon; MSKCC¼Memorial Sloan-Kettering Cancer Center;
RMME¼Repeated-measures mixed-effect model; VAS¼visual analogue scale.
aFor each continuous variable, the coefficient represents the quality of life per unit change in the
variable. For example, after controlling for baseline covariates, an increase in age of 1 year reduced the quality of life by 0.002. For each categorical variable, the coefficient
represents the quality of life as compared with the reference group, which is enclosed in parentheses. For example, patients treated with IFN-a had a lower quality of life by 0.099
compared with those treated with temsirolimus (reference group) after controlling for baseline covariates. *Po0.05.
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